Ryman Healthcare (NZSE:RYM) Stock Looks Fairly Valued Following Its 85% Five Year Fall

Ryman Healthcare has seen its share price fall sharply over several years, yet fresh sales momentum and high occupancy now put the spotlight squarely on whether the current NZ$1.83 price is supported by the cash the business can generate. With the stock rebounding over the past week after a tough year, the key issue for you is how those cash flows stack up against what the market is paying today.

• The share price has declined 85.3% over 5 years, which raises the question of how much of Ryman Healthcare's long term cash flow potential is already being discounted into the stock.

• Recent strong unit sales, tight retirement village inventory and 94.0% care occupancy may support expectations for more stable cash generation and influence how investors think about the timing and durability of future cash flows.

• What if you looked at Ryman Healthcare through its sales instead? See why Ryman Healthcare's 2.2x P/S tells a different valuation story .

For investors, the debate is whether the current NZ$1.83 share price is justified by Ryman Healthcare's cash flows when assessed against an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach.

If you are weighing Ryman Healthcare against other opportunities that also focus on cash generation, it can help to compare it with 198 high quality undervalued stocks .

Does Ryman Healthcare Look Fairly Valued on Cash Flow?

The Discounted Cash Flow (DCF) approach here looks at the cash Ryman Healthcare can return to shareholders over time and discounts it back to today. On the latest numbers, the business produced last twelve month free cash flow of about NZ$184.7m, with the model then assuming free cash flow steps down in the near term before settling into a slower declining path over the following decade. That pattern points to a profile that leans more on stabilising existing operations rather than on heavy expansion.

On this setup, the DCF suggests Ryman Healthcare's intrinsic value sits broadly in line with the current NZ$1.83 share price, given these cash flow and discount rate assumptions. Because the recent Q2 update highlighted strong sales volumes and high occupancy, the market reaction around NZ$1.83 looks consistent with a view that current cash generation is already well reflected in the price rather than being heavily discounted. Find out what Ryman Healthcare could be worth using our Discounted Cash Flow (DCF) estimate .

The Ryman Healthcare Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Ryman Healthcare pick up where the DCF puzzle leaves off and set out which paths for growth, profitability and earnings would need to occur for the share price to appear meaningfully higher or lower than it is today. Each scenario links its implied value to a specific view on how Ryman Healthcare's future growth rate, margins and key risks could change, providing a reference point that can be revisited as new information becomes available.